RecruitingPhase 1NCT05808634

Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.

An Open-label, Multicenter, Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Efficacy of BA3182, a Bispecific Epithelial Cell Adhesion Molecule (EpCAM)/CD3 Antibody, in Patients With Advanced Adenocarcinoma

Sponsor

BioAtla, Inc.

Enrollment

168 participants

Start Date

Jul 14, 2023

Study Type

INTERVENTIONAL

Conditions

Advanced Adenocarcinoma

Summary

The objective of this study is to assess safety and efficacy of BA3182 in Advanced Adenocarcinoma

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called BA3182 for people with advanced adenocarcinoma. The study is currently recruiting participants at 9 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGBA3182

Conditionally active biologic (CAB)-bispecific T-cell engager antibody construct targeting EpCAM

Locations(9)

UC Irvine

Irvine, California, United States

USC Norris Comprehensive Cancer Center

Los Angeles, California, United States

Yale Cancer Center

New Haven, Connecticut, United States

Northwestern University

Chicago, Illinois, United States

University of Illinois

Chicago, Illinois, United States

Karmanos Cancer Institute

Detroit, Michigan, United States

The Christ Hospital Cancer Center

Cincinnati, Ohio, United States

University Hospitals Cleveland Medical Center

Cleveland, Ohio, United States

Fred Hutch Cancer Center

Seattle, Washington, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05808634

Related Trials

A Prospective, Multi-center, Observational Study for Signal-C Test Evaluation

NCT060599631 location

A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma

NCT051013561 location